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Xanafide, a DNA-intercalating agent and topoisomerase II inhibitor, has previously demonstrated comparable cytotoxicity to the
parent drug amonafide (NSC 308847). The current study was conducted to investigate further the anti-proliferative effects of
xanafide in human breast cancer cell lines, in vitro and in vivo. The in vitro activity of xanafide against MCF-7, MDA-MB-231, SKBR-3 and
T47D cell lines was compared to that of paclitaxel, docetaxel, gemcitabine, vinorelbine and doxorubicin. In MCF-7, xanafide
demonstrated comparable total growth inhibition (TGI) concentrations to the taxanes and lower TGI values than gemcitabine,
vinorelbine and doxorubicin. MCF-7 (oestrogen receptor (ER)þ/p53 wild-type) was the most sensitive cell line to xanafide. MDA-
MB-231 and SKBR-3 exhibited similar sensitivity to xanafide. T47 D (ERþ/p53 mutated), showed no response to this agent. The in
vivo activity of xanafide was further compared to that of docetaxel in MCF-7 and MDA-MB-231 cell lines using the hollow fibre assay.
Xanafide was slightly more potent than docetaxel, at its highest dose in MCF-7 cell line, whereas docetaxel was more effective than
xanafide in MDA-MB-231 cell line. Our results show that there is no relationship between sensitivity of these cell lines to xanafide and
cellular levels of both isoforms of topoisomerase II and suggest that ER and p53 status and their crosstalk may predict the
responsiveness or resistance of breast cancer patients to xanafide.
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Breast cancer is the most common malignancy affecting women
in the Western world. Systemic chemotherapy is indicated for
women with metastatic breast cancer (MBC) that is oestrogen/
progesterone-negative or unresponsive to hormonal therapy,
or rapidly progressing and life-threatening (Hortobagyi and
Piccart-Gebhart, 1996). Several single-agent chemotherapeutic options
have been shown to be effective as first- or second-line therapy in
the management of MBC with the taxanes and anthracyclines being
among the most active drugs (Pronzato and Rondini, 2006).
The taxanes, paclitaxel and docetaxel, bind to, and stabilise
microtubules, causing cell-cycle arrest and apoptosis (Schiff et al,
1979). The overall response rates achieved in MBC patients were
29–63 and 47–65%, with paclitaxel and docetaxel, respectively
(Montero et al, 2005). However, side effects such as hypersensi-
tivity reactions, myelosuppression and neuropathy were observed
with the taxanes, although docetaxel causes less neuropathy and
more myelotoxicity (Ghersi et al, 2005).
Anthracyclines are active agents in primary adjuvant and palliative
treatment of breast cancer (Kroger et al, 1999). Doxorubicin
intercalates among DNA base pairs resulting in conformational
changes in DNA structure and changes in the activity of
topoisomerase. In MBC, response rates to single doxorubicin
treatment range from 52% in previously untreated patients to 28%
in patients previously exposed to an alkylating agent (Esteva et al,
2001). In patients who failed to respond to anthracycline and taxanes
treatment, administration of capecitabine, gemcitabine or vinor-
elbine has been shown to result in overall response rates of 20–25%
(Livingston et al, 1997; Blum et al, 1999; Valerio et al, 2001).
Gemcitabine, an antimetabolite pyrimidine analogue, and vinor-
elbine, which inhibits microtubule polymerisation, have been widely
investigated in the treatment of MBC (Martin et al, 2007).
In view of previous studies, in clinical practice, the potential
therapeutic impact of standard chemo-agents for breast cancer is
often limited due to intrinsic and/or acquired drug resistance in
addition to drug-related toxicity. Therefore, balancing efficacy
and toxicity is a major challenge, and the optimal choice of
chemotherapy must be driven by patient and disease character-
istics such as menopausal status, oestrogen and progesterone
receptor status, Her-2 neu expression (Gralow, 2005), and tumour
characteristics such as p53 gene involved in tumour response to
therapy (Vogelstein et al, 2000).
Given the current status of the breast cancer treatment and to
further improve the clinical outcome in these patients, new
treatment approaches are needed.
Naphthalimides are DNA-intercalating agents that bind to DNA
by insertion between the base pairs of the double helix.
Intercalation causes the base pairs to separate vertically, thereby
distorting the sugar-phosphate backbone and changing the degree
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sof rotation between successive base pairs. Naphthalimides were
designed by combining structural components of several anti-
tumour compounds into a small molecule and have shown high
antitumour activity upon a variety of murine and human tumour
cells (Brana and Ramos, 2001). One of these compounds,
amonafide (Sami et al, 1993) has been verified to exert ATP-
independent topo II-mediated DNA cleavage (Andersson et al,
1987; Hsiang et al, 1989; Dorr et al, 2001). Furthermore, this agent
is not affected by the multidrug resistance phenomenon and is not
an efflux pump substrate (Dorr et al, 2001).
In previous clinical studies, amonafide demonstrated activity
for the treatment of MBC (Costanza et al, 1995). However, it is
metabolised to an active but myelosuppressive metabolite, the
N-acetyl amonafide. A population study in women with breast
cancer established that wide variation in the major side-effect of
neutropenia was related to inter-individual patient differences in
N-acetylating activity. Importantly, at the same prescribed dose,
slow NAT2 acetylators were believed to be underdosed as reflected
by minimal response rate and lack of grade 3 myelosuppression
while rapid acetylators had greater haematologic toxicity attrib-
uted to slower clearance of the parent amonafide (Ratain et al,
1991, 1993). These data, and that from other studies in a variety of
major tumour types, led to the conclusion that amonafide should
not be considered for further clinical development.
Xanafide (amonafide L-malate), a novel salt formulation of
amonafide, has been developed. Preliminary pharmacological and
chemical equivalence studies demonstrated that xanafide had
comparable pharmacokinetics and toxicity in vitro and in vivo,
while having superior solubility, stability and compressibility than
the parent drug, amonafide (personal communication). Individua-
lising the dose of xanafide as a function of NAT2 phenotype may
optimise patient safety and therapeutic benefit. Xanafide has
recently received the FDA Orphan Drug Designation for the
treatment of acute myeloid leukaemia (AML) and has now entered
phase II clinical trials in patients with secondary AML.
The present study is the first one to report preclinical evaluation
of xanafide. Our aim was to compare xanafide activity to standard
breast cancer agents (paclitaxel, docetaxel, vinorelbine, gemcita-
bine and doxorubicin) in a panel of four breast cancer cell lines:
MCF-7, MDA-MB-231, SKBR-3 and T47D, in vitro, and against
paclitaxel in the first two cell lines, in vivo. This panel included
oestrogen receptor (ER)-positive and ER-negative cell lines, since
it has been shown that oestrogen can enhance the effects of
topoisomerase II inhibitors in ER-responsive breast cell lines
(Epstein and Smith, 1988).
MATERIALS AND METHODS
Cell lines
MCF-7, MDA-MB-231, SKBR-3 and T47D were obtained from the
American Type Culture Collection (ATCC) (Rockville, MD, USA).
Cell lines were grown in RPMI-1640 medium (Invitrogen,
Gaithersburg, MD, USA), supplemented with 10% fetal bovine
serum, 2mML -glutamine at 371C in a humidified atmosphere
containing 5% CO2.
Chemicals and compounds
All general chemicals were purchased from Sigma Chemical Co. (St
Louis, MO, USA) unless otherwise specified. Xanafide was kindly
provided by Xanthus Life Sciences. Paclitaxel, docetaxel, doxorubi-
cin, vinorelbine and gemcitabine are commercially available. Before
in vitro use, a 1mM stock solution of each agent was prepared by
dilution in culture media. Polyvinylidene fluoride hollow fibres
(500000Da molecular weight cutoff, 1.0mm ID) were purchased
from Spectrum Medical Industries (Luguan Hills, CA, USA).
Animals
Athymic NCr nu/nu mice, 5–6 weeks of age were purchased from
Taconic (Germantown, NY, USA). All studies involving these
animals were conducted in accordance with National Cancer
Institute (NCI) protocol and the McGill University Animal Care
and Ethics guidelines.
Cytotoxicity assay
Cytotoxicity studies were performed using the sulphorhodamine B
assay (Skehan et al, 1990). Cytotoxicity of each drug was evaluated
by the GI50 and TGI values, representing the 50% growth inhibition
and total growth inhibition, respectively, compared to non-treated
control (C) and a control at time of addition of increasing drug
concentrations (Tz). On day 1, MCF-7 & SKBR-3 (5000 cells) and
MDA-MB-231 & T47D (20000 cells) were seeded into 96-well
plates in a volume of 100ml per well. On day 2, one plate of each
cell line was fixed in situ with trichloroacetic acid (TCA) to
establish the cell population at time of drug addition (Tz). An
aliquot of 100ml of serial dilutions of the different agents was
added to the appropriate well, resulting in a series of final
concentrations ranging from 0.1nM to 100mM. After 48h of drug
exposure, the medium in control and drug-containing wells was
removed. Cells were washed with cold phosphate-buffered saline
(PBS) and then precipitated with 50ml ice-cold 50% TCA and fixed
for 60min at 41. The supernatant was discarded, and cells were
washed five times with tap water and air-dried. Fixed cells were
then dyed with 50ml of 0.4% sulphorhodamine B in 1% acetic acid
solution and the plates were incubated for 10min at room
temperature. Unbound dye was removed by washing with 1%
acetic acid and the plates were air-dried. Sulphorhodamine B was
dissolved in 150mlo f1 0 m M Tris-buffer (pH 10.5) and 540nm
optical density was measured in a Labsystems Multiskan
s
Multisoft apparatus. Percent net growth was calculated using the
seven absorbance measurements (time zero, (Tz), growth control,
(C), plus the test growth at the different drug concentration levels
(Ti)) as follows: ((Ti–Tz)/(C–Tz)) 100 for concentrations for
which Ti4/¼Tz and ((Ti–Tz)/Tz) 100 for concentrations for
which TioTz. The results are expressed as the mean of three
independent experiments7s.e.m.
Evaluation of xanafide antitumour activity using the
in vivo hollow fibre assay
The in vivo hollow fibre test was performed using the original NCI
protocol (Hollingshead et al, 1995). Confluent monolayers of
MCF-7 and MDA-MB-231 cells were harvested, collected by centrifuga-
tion and resuspended in conditioned medium. In preliminary NCI
studies, cell growth was assessed with fibres containing various
cell densities. As a result, cell densities of 2.5 10
6 and 5 10
6
cellsml
 1 were found to be suitable for drug studies with MCF-7
and MDA-MB-231 cell lines, respectively. Fibres filled with cells at
the respective densities were incubated in 6-well plates overnight
at 371C in a 5% CO2 atmosphere. Female athymic NCr nu/nu mice
at 5–6 weeks of age were obtained from Taconic. Each mouse
hosted up to six fibres, which were cultured in two physiological
compartments. For intraperitoneal (i.p.) implants, a small incision
was made through the skin and musculature of the dorsal
abdominal wall, the fibre samples were inserted into the peritoneal
cavity in a craniocaudal direction and the incision was closed with
skin staples. For subcutaneous (s.c.) implants, a small skin incision
was made at the nape of the neck to allow insertion of an 11-gauge
tumour implant trocar. The trocar, containing the hollow fibre
samples, was inserted caudally through the s.c. tissues and fibres
were deposited during withdrawal of the trocar. The incision was
closed with a skin staple.
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sMice were randomised into three groups: saline control group
(n¼6), xanafide and docetaxel treated groups (n¼3 for each
group). Xanafide was dosed at the maximum tolerated dose
30mgkg
 1, on the basis of reported in vivo studies with amonafide
(Dorr et al, 2001), and docetaxel at 5 and 12.5mgkg
 1 based on
previous paclitaxel NCI tested doses (Hollingshead M, unpublished
data). Both agents, in PBS were given once daily by i.p. injection
from day 3–7 after implantation as reported previously
(Hollingshead et al, 1995). Animals were monitored daily and clinical
signs and body weights were recorded daily.
On day 8, mice were killed and fibres were retrieved. The fibres
were placed into 6-well plates, with each well containing 2ml of
fresh, prewarmed culture medium and allowed to equilibrate for
30min at 371C. To define the viable cell mass contained within the
intact hollow fibres, a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) dye conversion assay was used. Briefly,
1ml of prewarmed culture medium containing 1mg MTTml
 1 was
added to each dish. After incubating at 371C for 4h, the culture
medium was aspirated and the samples were washed twice with
normal saline containing 2.5% protamine sulphate solution
followed by overnight incubation at 41C. To assess the optical
density of the samples, the fibres were transferred to 24-well
plates, cut in half and allowed to dry overnight. The formazan
was extracted from each sample with dimethylsulphoxide
(250mlwell
 1) for 4h at room temperature on a rotation platform.
Aliquots (150ml) of extracted MTT formazan were transferred to
individual wells of 96-well plates and assessed for optical density at
a wavelength of 540nm. Results are expressed as % growth
inhibition compared to control7s.d.
Statistical analysis
The comparisons between the untreated and treated groups were
analyzed using the Student’s t-test. Two-sided P-values less than
0.05 were considered statistically significant.
RESULTS
In vitro antiproliferative activity of xanafide in human
breast cancer cells
A panel of four human breast cancer cell lines: MCF-7, MDA-MB-
231, SKBR-3 and T47D was used in this study. Their molecular
characteristics are listed in Table 1. Using the SRB assay, the
cytotoxicity profile of xanafide was compared with those of five
anticancer drugs widely used in the clinic: paclitaxel, docetaxel,
doxorubicin, gemcitabine and vinorelbine. The results were
expressed as GI50 and TGI values and summarised in Table 2.
After 48h exposure time, xanafide demonstrated a steep
response curve in the four breast cell lines tested (Figure 1A–D).
Xanafide inhibited the growth of the ER-positive MCF-7 and
T47D cells in a concentration-dependent manner, with an
average GI50 value of 5 and 20mM, respectively. Xanafide also
inhibited the growth of the ER-negative SKBR-3 and MDA-MB-231
cells in a concentration-dependent manner, with an average GI50
value of 6 and 10mM, respectively (Table 2). T47 D was the less
sensitive to the antiproliferative effect of xanafide (Figure 1D).
Notably, no total growth inhibition of T47D was obtained which
could, in part, be due to the long doubling time of this cell line
(45.5h).
To better visualise the differences in the cytotoxicity to achieve
complete cell growth inhibition for all the agents, TGI concentra-
tions (resulting in total growth inhibition) were expressed. At
doses higher than the TGIs, net cell killing was observed in the four
breast cell lines tested: MCF-7, MDA-MB-231, SKBR-3 and T47D
(Table 2).
In MCF-7 cell line, xanafide exhibited a 1.7–2.2-fold lower TGI
concentration than those of docetaxel and paclitaxel, respectively.
Vinorelbine and doxorubicin induced similar effects and their TGI
concentrations were 10-fold higher than that of xanafide. No total
growth inhibition was achieved with gemcitabine (Table 2).
In MDA-MB-231 cell line, doxorubicin induced total growth
inhibition at the lowest concentrations: 15mM, whereas paclitaxel,
docetaxel and xanafide exhibited comparable TGI values: 20, 25
and 35mM. Vinorelbine and gemcitabine were less potent as shown
by their respective 2.6- to 5.7-fold higher TGI concentrations,
respectively (Table 2).
In SKBR-3 cells, gemcitabine and docetaxel induced total growth
inhibition at 30mM. Paclitaxel, xanafide and vinorelbine exhibited
comparable TGI concentrations, 35, 45 and 50mM, respectively.
The TGI for doxorubicin was 80mM, 9-fold higher than that of
xanafide (Table 2).
In T47D cell line, vinorelbine and gemcitabine induced similar
cytotoxicity (TGI concentration of 17mM). Paclitaxel and docetaxel
showed TGI concentrations of 35 and 60mM, respectively. Xanafide
did not induce any complete growth inhibition in this cell line
(Table 2).
These results indicate that the four breast cell lines tested
exhibited differential sensitivity to xanafide and the common
chemotherapeutic agents tested. Considering the TGI concentra-
tions (Table 2) and the net cell killing achieved by xanafide,
MCF-7 was the most sensitive cell line; MDA-MB-231 and SKBR-3
were almost equally sensitive while T47D was less responsive to
this agent.
In vivo antitumour activity
On the basis of its cytotoxic activity in vitro, xanafide was further
evaluated for in vivo activity in two ERþ and ER  breast cancer
cell lines, MCF-7 and MDA-MB-231, respectively. The two cell lines
were implanted i.p. and s.c. in NCr nude mice using the hollow
fibre assay. Animals were treated with saline (control group),
docetaxel dosed at 5 and 12.5mgkg
 1, i.p., or xanafide at
30mgkg
 1, i.p. on a q.d. 5 treatment schedule, beginning on
day 2 post-fibre implantation (days 3–7).
As shown in Figure 2, in the fibres retrieved from the i.p. sites,
xanafide, administered as single agent, was effective at reducing
the tumour cells growth of MCF-7 and MDA-MB-231 by 41 and
Table 1 Characteristics of breast cell lines
Topo-II levels (absorbance)
a
Cell line ER status p53 status Her levels ab
MCF-7 + wt Very low 1086 1233
MDA-MB-231   mu Low 724 304
SKBR-3   mu High 1656 (amplified) 1202 (amplified)
T47D + mu Moderate 588 1188
Abbreviation: ER¼oestrogen receptor.
aHoulbrook et al (1995).
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s46%, respectively, as compared with control (Po0.05). Docetaxel
exhibited dose-dependent growth inhibitory effects. At the lowest
dose used, 5mgkg
 1, docetaxel produced a growth inhibition of 36
and 45%, in MCF-7 and MDA-MB-231, respectively (Po0.05). At
12.5mgkg
 1, the growth inhibition elicited was 39 and 51%, in
MCF-7 and MDA-MB-231, respectively (Po0.05). These results
show that xanafide was slightly more potent than docetaxel at its
highest dose, in MCF-7. In contrast, its potency was lower than
that of docetaxel in MDA-MB-231.
In the fibres retrieved from the s.c. sites (Figure 2), xanafide
administered as single agent produced comparable growth
inhibition in MCF-7 and MDA-MB-231 cell lines, reducing the
growth by 42 and 40%, respectively (Po0.05). Docetaxel showed
dose-dependent inhibitory effects. At the lowest dose, the growth
inhibition obtained was 31 and 36%, in MDA-MB-231 and MCF-7,
respectively (Po0.05). At the highest dose used, 12.5mgkg
 1,
the growth inhibition induced was 42 and 46%, in MCF-7 and
MDA-MB-231, respectively (Po0.05).
Body weights were recorded daily during the course of the study,
and expressed as the difference observed relative to start of
treatment. For the docetaxel treated mice no loss in body weight
was observed while in the xanafide treated mice, body weight was
reduced by 12% by day 8, which was within the acceptable range
based on NCI established criteria (Figure 3).
DISCUSSION
Amonafide, a DNA-intercalating agent and topoisomerase II
inhibitor, has been used as first-line treatment for MBC. However,
amonafide is extensively metabolised, including N-acetylation to
an active metabolite, N-acetyl amonafide, and the extent of
amonafide N-acetylation is the major determinant of myelosup-
pression (Ratain et al, 1995). As a result, several compounds
having structural analogy to amonafide have been synthesized
(Sami et al, 1993, 2000; Dorr et al, 2001). Among these, azonafide
has shown high potency against a panel of human colon cancer cell
lines and was active against i.p. P388 leukaemia and s.c. B16
melanoma murine models (Sami et al, 1993).
Xanafide, the new formulation of amonafide, has been
synthesized aiming at reducing the toxicity and improving the
therapeutic index of the parent drug, amonafide. We have
previously shown that xanafide and amonafide hydrochloride
have comparable and significant inhibitory activity both in vitro
against the three cell lines of the NCI prescreen program: H460
(non-small cell lung), SF268 (glioma) and MCF-7 (breast), and in
vivo in MCF-7 (breast), COLO205 (colon) and PC-3 (prostate) cell
lines, using the hollow fibre assay (Alami et al, 2003).
The aim of this study was to further investigate the antitumour
effects of xanafide, in comparison with common breast drugs in a
Table 2 In vitro profile of xanafide in comparison with common drugs
GI50/TGI7s.e.m. (lM)
MCF-7 MDA-MB-231 SKBR-3 T47D
Xanafide 571.1 971.8 1071.5 3575.1 670.9 4575.3 2072.2 —
Paclitaxel 0.0170.004 2071.9 0.170.04 2072.1 170.3 3574.3 0.170.02 3573.7
Docetaxel 0.00170.0005 1571.8 570.9 2572.8 571.0 3074.1 0.0170.006 6075.5
Gemcitabine 0.570.04 — 170.4 4100 0.170.03 3074.0 0.570.07 1772.3
Vinorelbine 571.3 100710.2 570.7 907 270.3 5075.6 0.570.05 1772.2
Doxorubicin 0.570.06 100718.3 0.570.003 1571.8 4073.8 8077.8 170.3 1007
GI50 and TGI concentrations calculated after 48h exposure. Results are mean of three independent experiments. GI50 was calculated as the drug concentration that reduced
the number of cells to 50% of the number of cells before drug addition. TGI is the drug concentration that achieved total growth inhibition of the cells.
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Figure 1 In vitro cytotoxicity of xanafide in breast cell lines in comparison with common drugs. (A) MCF-7, (B) MDA-MB-231, (C) SKBR-3, (D) T47D.
Xanafide (K), vinorelbine (m), gemcitabine (’), doxorubicin (J), paclitaxel (n) and docetaxel (&). Cells were exposed to the different drugs for 48h. %
Net growth was determined with the SRB assay as described in Materials and Methods. The results are the average of three separate experiments7s.e.m.
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spanel of breast cell lines well characterised for their oestrogen
receptor, p53 status, Her-2 and topoisomerase II a and b levels:
MCF-7, MDA-MB-231, SKBR-3 and T47D (Table 1). Xanafide
exhibited a steep response curve in all four cell lines tested
(Figure 1A–D). The GI 50 and TGI concentrations clearly show
that these cell lines displayed differential sensitivity to xanafide
with MCF-7 (ER
þ/p53 wild-type) being the most sensitive and T47
D (ERþ/p53 mutated) the most resistant. Although this cell line
was responsive to low doses of the other drugs tested, the lack of
activity of xanafide in the T47D could be, in part, due to its long
doubling time.
Furthermore, xanafide has proved to be more active than the
taxanes, gemcitabine, vinorelbine and doxorubicin in MCF-7.
The Two ER
 /p53 mutated cell lines (MDA-MB-231 and SKBR-3)
displayed comparable in vitro responsiveness to xanafide as
demonstrated by their respective GI50 and TGI concentrations
(Table 2).
Our in vitro results correlate with the in vivo data where
xanafide was slightly more potent than docetaxel at its highest
dose, in MCF-7 (Figure 2). These findings suggest a specificity of
xanafide against the ER
þ, p53 w/t MCF-7 cell line.
These data raise the question of what are the mechanisms
underlying the response to xanafide. Several clinical observations
indicate a role for oestrogen and ER in the development,
progression and treatment of human breast cancer (Angeloni
et al, 2004). In addition, there is substantial evidence showing that
alterations in the tumour suppressor gene, p53, are associated with
the development of several types of cancer, including breast cancer
(Hollstein et al, 1991). Considering that the p53 gene is mutated in
approximately 50% of all tumours, its role in the control of cell
cycle progression, maintenance of DNA integrity and induction of
apoptosis is well documented (Zhan et al, 1993; Yonish-Rouach
et al, 1995). It has also been shown that in breast cancer, p53
mutations are associated with a decrease in disease-free and
overall survival of patients (Sirvent et al, 2001). Previous studies
have reported that the ability of p53 to control the expression of
ERa could suggest that specific p53 mutations in breast tumours
may contribute not only to oncogenesis and drug resistance, but
also to the more aggressive phenotype associated with the loss of
ER expression. Interestingly, a high percentage of breast tumours
with p53 mutations are ER-negative (Berns et al, 1996).
Our results showed that the two ER
 /p53 mutated cell lines
MDA-MB-231 and SKBR-3 exhibited moderate sensitivity to
xanafide, whereas T47 D (ERþ/p53 mutated) was more resistant
to xanafide, with no induced cell killing, as compared with
the extent of the anti-proliferative effect observed with MCF-7
(ERþ/p53 wt) (Table 2). These findings may partially support a
mechanism of responsiveness to xanafide in ERþ breast cancer
where an active p53 gene is required. Additionally, related studies
have shown that p53 was a negative regulator of the ER signalling
pathways, suggesting a crosstalk between p53 and ER in breast
cancer (Yu et al, 1997).
On the other hand, the DNA damage induced by topo II
inhibitors triggers the p53-dependent apoptotic pathway that lead
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and s.c. fibres filled with MCF-7 and MDA-MB-231 breast cell lines. Mice
were treated with vehicle (—J—), xanafide (—K—), docetaxel
(5mgkg
 1) (—m—) and docetaxel (12.5mgkg
 1)( — ’—).
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Figure 2 Antitumour effect of xanafide in comparison with docetaxel in MCF-7 and MDA-MB-231 breast cell lines in the in vivo hollow fibre assay. Fibres
filled with the cells were implanted at the intraperitoneal (i.p.) and subcutaneous (s.c.) compartments of NCr nu/nu mice. The animals were treated with
saline (control), xanafide (30mgkg
 1) or docetaxel (5 & 12.5mgkg
 1). Drugs were administrated once daily by i.p. injection from days 3–7 after
implantation. On day 8, mice were killed and fibres were retrieved. The effectiveness of the drugs was evaluated on the basis of growth inhibition of the cells
determined by MTT assay, as described in Materials and Methods.
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sto cell cycle arrest (p21, cyclins, GADD45, PCNA) or to apotosis
(Bcl-2, Bax, surviving, scotin) (Valkov and Sullivan, 2003). Related
studies using tumour cell lines tested for their p53 status have
shown that mutations of p53 correlate with drug resistance to a
wide spectrum of anticancer agents, including topo II inhibitors
(O’Connor et al, 1997; Sirvent et al, 2001). Usually, wild-type p53
expression predisposes cells to a more rapid rate of cell death after
DNA damage. Previous studies have reported that non-small cell
lung cancer cells having p53 mutations showed significantly poorer
response to intensive chemotherapy that included etoposide and
epirubicin (Vogt et al, 2002). In addition, treatment of MCF-7 with
doxorubicin resulted in an increase of p53 expression, confirming
a p53-mediated response to doxorubicin in cells containing a wild-
type p53 gene product (Liem et al, 2003). Additional work has
revealed that loss of wild-type p53 function confers resistance to
etoposide in neuroblastoma cells (Keshelava et al, 2001) and in
glioma cells (Yin et al, 2000). Others have also reported that p53
status in breast cancer patients correlated with a poor response to
epirubicin (Mottolese et al, 2000). Furthermore, it has been
postulated that the cell cycle arrest effect of wild-type p53 on cell
cycle regulated topo IIa expression could potentially provide a
sufficient amount of target enzyme for optimisation of treatment
with topoisomerase II inhibitors (Valkov and Sullivan, 2003), thus
supporting the greater potency of xanafide in MCF-7 cell line.
In addition, the topoisomerase II a gene, TOP2 a, is located at
chromosome band 17q12-q21, close to the ErbB-2 oncogene (HER-
2/neu), which is the most commonly amplified oncogene in breast
cancer. Because of the physical proximity to ErbB-2, copy number
aberrations may also occur in the topoIIa gene, which may be
related to the altered chemosensitivity to topoII inhibitors
(Jarvinen and Liu, 2006). Our results show that xanafide sensitivity
was not correlated with expression levels of both topoisomerase II
a and b. Considering the TGI concentrations, MDA-MB-231 and
SKBR-3 expressing low levels and high levels of both isoforms,
respectively, exhibited comparable sensitivity to xanafide. Our data are
in agreement with those reported by Tewey et al (1984) where
sensitivity to the topo II inhibitor, doxorubicin, showed no correlation
with expression of either of the topoisomerase II isoforms.
In view of the previous findings together with our results, we
speculate that p53 and ER and their signalling pathways are likely
important determinants of breast tumour cells sensitivity to xanafide.
Understanding these relationships may lead to strategies for xanafide-
based chemotherapy optimisation and further precision targeting of
tumour cells to avoid drug resistance and thereby chemotherapy
failure. Furthermore, the steep response curves of xanafide activity in
the four breast cell lines tested suggest that accurate individualised
patient dosing is critically important for maximising clinical response
while minimising neutropenic variability.
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